Literature DB >> 33772623

Association between genetic variations in carbamoyl-phosphate synthetase gene and persistent neonatal pulmonary hypertension.

Nashwa El-Khazragy1, Mohamed El Barbary2, Hala Fouad3, Abdallah Abdelgawad4, Dina Rabie2.   

Abstract

Persistent pulmonary hypertension of the new-borns (PPHN) is one of the main etiologies of morbidity as well as mortality in neonates. Previous studies found that genetic polymorphisms in urea cycle enzymes are associated with PPHN. Few of the genetic polymorphisms in neonates have been recognized with PPHN. We aimed to find out the prevalence of the CPS-I gene polymorphism and to correlate the genotype with the serum nitric oxide (NO) levels in Egyptian neonates with idiopathic PPHN. We included neonates diagnosed with PPH (n = 150) while the control group included healthy neonates with matched age and sex (n = 100). The CPS-I gene polymorphism: A/C, trans-version substitution, rs4399666 genotype was identified using TaqMan-based quantitative PCR. The results revealed that the CPS-I A/C rs4399666 gene polymorphism and lower serum NO levels were significantly associated with idiopathic PPHN in neonates. In addition, serum NO level was significantly associated with an rs4366999 A/C variant gene in idiopathic PPHN (p = 0.001). Univariable regression analysis demonstrated that there was a significant association between CPS-I A/C rs4399666 CC and increased risk of PPHN (odd ratio, 95% CI of 1.8 (0.78 to 1.75), p-value = 0.04).
Conclusion: We concluded that mutant CPS-I A/C rs4399666 minor variant especially the homozygous CC genotype is frequently distributed among the PPHN group. This demonstrates that the presence of mutant CPS-I rs4399666 does not necessarily predispose to the development of PPHN in neonates, but nonetheless, if the C allele is inherited in the homozygous CC genotype, it is associated with a higher risk of PPHN. What is Known: • Prior studies found that polymorphisms in urea cycle enzyme genes are associated with PPHN. • Association between CPS-1 gene polymorphisms is significantly associated with PPHN. What is New: • The prevalence of CPS-1, A/C trans-version substitution, rs4399666 gene polymorphism in Egyptian neonates presented with idiopathic PPHN. • Mutant CPS-I A/C rs4399666 especially the homozygous CC genotype is more frequently distributed among PPHN, and it is significantly associated with low serum nitric oxide level.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Carbamoyl-phosphate synthetase polymorphism; Genetics; Idiopathic persistent pulmonary hypertension; Neonates; Nitric oxide

Mesh:

Substances:

Year:  2021        PMID: 33772623     DOI: 10.1007/s00431-021-04053-8

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  22 in total

1.  Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes.

Authors:  M C Walsh-Sukys; J E Tyson; L L Wright; C R Bauer; S B Korones; D K Stevenson; J Verter; B J Stoll; J A Lemons; L A Papile; S Shankaran; E F Donovan; W Oh; R A Ehrenkranz; A A Fanaroff
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

2.  Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.

Authors:  Anne Hilgendorff; Christian Apitz; Damien Bonnet; Georg Hansmann
Journal:  Heart       Date:  2016-05       Impact factor: 5.994

Review 3.  Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  Mei-Yin Lai; Shih-Ming Chu; Satyan Lakshminrusimha; Hung-Chih Lin
Journal:  Pediatr Neonatol       Date:  2017-08-10       Impact factor: 2.083

4.  Persistent pulmonary arterial hypertension in the newborn (PPHN): a frequent manifestation of TMEM70 defective patients.

Authors:  Michela Catteruccia; Daniela Verrigni; Diego Martinelli; Alessandra Torraco; Teresa Agovino; Luisa Bonafé; Adele D'Amico; Maria Alice Donati; Rachele Adorisio; Filippo Maria Santorelli; Rosalba Carrozzo; Enrico Bertini; Carlo Dionisi-Vici
Journal:  Mol Genet Metab       Date:  2014-01-08       Impact factor: 4.797

5.  Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide.

Authors:  Paul H Lipkin; Dennis Davidson; Lynn Spivak; Richard Straube; Jared Rhines; C T Chang
Journal:  J Pediatr       Date:  2002-03       Impact factor: 4.406

6.  Variations in CRHR1 are associated with persistent pulmonary hypertension of the newborn.

Authors:  Heather M Byers; John M Dagle; Jonathan M Klein; Kelli K Ryckman; Erin L McDonald; Jeffrey C Murray; Kristi S Borowski
Journal:  Pediatr Res       Date:  2011-12-21       Impact factor: 3.756

7.  Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response.

Authors:  Judith M Vonk; Dirkje S Postma; Harm Maarsingh; Marcel Bruinenberg; Gerard H Koppelman; Herman Meurs
Journal:  Pharmacogenet Genomics       Date:  2010-03       Impact factor: 2.089

Review 8.  Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn.

Authors:  Steven H Abman
Journal:  Neonatology       Date:  2007-06-07       Impact factor: 4.035

9.  Persistent Pulmonary Hypertension of the Newborn in Late Preterm and Term Infants in California.

Authors:  Martina A Steurer; Laura L Jelliffe-Pawlowski; Rebecca J Baer; J Colin Partridge; Elizabeth E Rogers; Roberta L Keller
Journal:  Pediatrics       Date:  2016-12-01       Impact factor: 7.124

10.  Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society.

Authors:  Steven H Abman; Georg Hansmann; Stephen L Archer; D Dunbar Ivy; Ian Adatia; Wendy K Chung; Brian D Hanna; Erika B Rosenzweig; J Usha Raj; David Cornfield; Kurt R Stenmark; Robin Steinhorn; Bernard Thébaud; Jeffrey R Fineman; Titus Kuehne; Jeffrey A Feinstein; Mark K Friedberg; Michael Earing; Robyn J Barst; Roberta L Keller; John P Kinsella; Mary Mullen; Robin Deterding; Thomas Kulik; George Mallory; Tilman Humpl; David L Wessel
Journal:  Circulation       Date:  2015-11-03       Impact factor: 29.690

View more
  1 in total

Review 1.  Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.

Authors:  Helen Christou; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-25       Impact factor: 4.733

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.